689 related articles for article (PubMed ID: 28453743)
21. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
22. Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations.
Boisseau W; Euskirchen P; Mokhtari K; Dehais C; Touat M; Hoang-Xuan K; Sanson M; Capelle L; Nouet A; Karachi C; Bielle F; Guégan J; Marie Y; Martin-Duverneuil N; Taillandier L; Rousseau A; Delattre JY; Idbaih A
Oncologist; 2019 Dec; 24(12):1584-1592. PubMed ID: 31346129
[TBL] [Abstract][Full Text] [Related]
23. A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.
Hatae R; Hata N; Suzuki SO; Yoshimoto K; Kuga D; Murata H; Akagi Y; Sangatsuda Y; Iwaki T; Mizoguchi M; Iihara K
Neuropathology; 2017 Jun; 37(3):191-199. PubMed ID: 27792249
[TBL] [Abstract][Full Text] [Related]
24. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations.
Miklja Z; Pasternak A; Stallard S; Nicolaides T; Kline-Nunnally C; Cole B; Beroukhim R; Bandopadhayay P; Chi S; Ramkissoon SH; Mullan B; Bruzek AK; Gauthier A; Garcia T; Atchison C; Marini B; Fouladi M; Parsons DW; Leary S; Mueller S; Ligon KL; Koschmann C
Neuro Oncol; 2019 Aug; 21(8):968-980. PubMed ID: 30805642
[TBL] [Abstract][Full Text] [Related]
25. Integrating a Large Next-Generation Sequencing Panel into the Clinical Diagnosis of Gliomas Provides a Comprehensive Platform for Classification from FFPE Tissue or Smear Preparations.
Parilla M; Kadri S; Patil SA; Fitzpatrick C; Ritterhouse L; Segal J; Collins J; Pytel P
J Neuropathol Exp Neurol; 2019 Mar; 78(3):257-267. PubMed ID: 30698790
[TBL] [Abstract][Full Text] [Related]
26. Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors.
Pincez T; Clément N; Lapouble E; Pierron G; Kamal M; Bieche I; Bernard V; Fréneaux P; Michon J; Orbach D; Aerts I; Pacquement H; Bourdeaut F; Jiménez I; Thébaud E; Oudot C; Vérité C; Taque S; Owens C; Doz F; Le Tourneau C; Delattre O; Schleiermacher G
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896933
[TBL] [Abstract][Full Text] [Related]
27. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
[TBL] [Abstract][Full Text] [Related]
28. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.
Nikiforova MN; Wald AI; Melan MA; Roy S; Zhong S; Hamilton RL; Lieberman FS; Drappatz J; Amankulor NM; Pollack IF; Nikiforov YE; Horbinski C
Neuro Oncol; 2016 Mar; 18(3):379-87. PubMed ID: 26681766
[TBL] [Abstract][Full Text] [Related]
29. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
30. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
31. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
32. Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification.
Gierke M; Sperveslage J; Schwab D; Beschorner R; Ebinger M; Schuhmann MU; Schittenhelm J
J Cancer Res Clin Oncol; 2016 Jan; 142(1):89-100. PubMed ID: 26115961
[TBL] [Abstract][Full Text] [Related]
33. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
34. Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
Synhaeve NE; van den Bent MJ; French PJ; Dinjens WNM; Atmodimedjo PN; Kros JM; Verdijk R; Dirven CMF; Dubbink HJ
Acta Neuropathol Commun; 2018 Nov; 6(1):126. PubMed ID: 30470264
[TBL] [Abstract][Full Text] [Related]
35. High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication-a comprehensive clinical, radiographic, pathologic, and genomic analysis.
Ferris SP; Velazquez Vega J; Aboian M; Lee JC; Van Ziffle J; Onodera C; Grenert JP; Saunders T; Chen YY; Banerjee A; Kline CN; Gupta N; Raffel C; Samuel D; Ruiz-Diaz I; Magaki S; Wilson D; Neltner J; Al-Hajri Z; Phillips JJ; Pekmezci M; Bollen AW; Tihan T; Schniederjan M; Cha S; Perry A; Solomon DA
Brain Pathol; 2020 Jan; 30(1):46-62. PubMed ID: 31104347
[TBL] [Abstract][Full Text] [Related]
36. Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing.
Ishida H; Iguchi A; Aoe M; Takahashi T; Tamefusa K; Kanamitsu K; Fujiwara K; Washio K; Matsubara T; Tsukahara H; Sanada M; Shimada A
Ann Hematol; 2019 Mar; 98(3):657-668. PubMed ID: 30446805
[TBL] [Abstract][Full Text] [Related]
37. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
[TBL] [Abstract][Full Text] [Related]
38. A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology.
Lorenz J; Rothhammer-Hampl T; Zoubaa S; Bumes E; Pukrop T; Kölbl O; Corbacioglu S; Schmidt NO; Proescholdt M; Hau P; Riemenschneider MJ
Acta Neuropathol Commun; 2020 Aug; 8(1):124. PubMed ID: 32758285
[TBL] [Abstract][Full Text] [Related]
39. Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology.
Linzey JR; Marini BL; Pasternak A; Smith C; Miklja Z; Zhao L; Kumar-Sinha C; Paul A; Harris N; Robertson PL; Hoffman LM; Chinnaiyan A; Mody R; Koschmann C
J Neurooncol; 2018 Mar; 137(1):155-169. PubMed ID: 29235051
[TBL] [Abstract][Full Text] [Related]
40. Childhood brain tumors: current management, biological insights, and future directions.
Pollack IF; Agnihotri S; Broniscer A
J Neurosurg Pediatr; 2019 Mar; 23(3):261-273. PubMed ID: 30835699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
